TransMedics Group, Inc. (NASDAQ:TMDX) Stock Position Decreased by Peregrine Capital Management LLC

Peregrine Capital Management LLC lessened its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX – Get Rating) by 2.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 134,888 shares of the company’s stock after selling 4,074 shares during the period. Peregrine Capital Management LLC owned 0.42% of TransMedics Group worth $8,325,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the business. BlackRock Inc. grew its position in shares of TransMedics Group by 16.1% during the 3rd quarter. BlackRock Inc. now owns 2,198,654 shares of the company’s stock valued at $91,771,000 after buying an additional 304,600 shares during the last quarter. Vanguard Group Inc. grew its position in TransMedics Group by 14.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,644,691 shares of the company’s stock worth $68,650,000 after purchasing an additional 208,377 shares during the last quarter. Lord Abbett & CO. LLC bought a new position in TransMedics Group in the 3rd quarter worth about $32,227,000. State Street Corp grew its position in TransMedics Group by 5.6% in the 3rd quarter. State Street Corp now owns 694,142 shares of the company’s stock worth $28,973,000 after purchasing an additional 36,716 shares during the last quarter. Finally, Bellevue Group AG grew its position in TransMedics Group by 12.7% in the 3rd quarter. Bellevue Group AG now owns 653,814 shares of the company’s stock worth $27,290,000 after purchasing an additional 73,927 shares during the last quarter. Institutional investors own 88.58% of the company’s stock.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, VP John F. Carey sold 1,410 shares of the company’s stock in a transaction that occurred on Tuesday, January 17th. The shares were sold at an average price of $62.71, for a total value of $88,421.10. Following the transaction, the vice president now owns 14,120 shares in the company, valued at approximately $885,465.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other TransMedics Group news, VP John F. Carey sold 1,410 shares of the company’s stock in a transaction that occurred on Tuesday, January 17th. The shares were sold at an average price of $62.71, for a total value of $88,421.10. Following the transaction, the vice president now owns 14,120 shares in the company, valued at approximately $885,465.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Waleed H. Hassanein sold 7,500 shares of the stock in a transaction on Tuesday, January 17th. The stock was sold at an average price of $64.14, for a total transaction of $481,050.00. Following the transaction, the chief executive officer now owns 418,785 shares in the company, valued at approximately $26,860,869.90. The disclosure for this sale can be found here. In the last quarter, insiders have sold 174,538 shares of company stock worth $12,508,017. 8.70% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Canaccord Genuity Group upped their target price on shares of TransMedics Group from $68.00 to $78.00 and gave the stock a “buy” rating in a research report on Thursday, February 23rd. Morgan Stanley upped their target price on shares of TransMedics Group from $63.00 to $74.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 23rd. Oppenheimer upped their price target on shares of TransMedics Group from $55.00 to $85.00 and gave the stock an “outperform” rating in a research note on Thursday, February 23rd. Cowen upped their price target on shares of TransMedics Group from $70.00 to $75.00 and gave the stock an “outperform” rating in a research note on Thursday, February 23rd. Finally, JPMorgan Chase & Co. upped their price target on shares of TransMedics Group from $67.00 to $81.00 and gave the stock an “overweight” rating in a research note on Thursday, February 23rd. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, TransMedics Group has an average rating of “Moderate Buy” and an average target price of $71.57.

TransMedics Group Stock Performance

TMDX stock opened at $73.30 on Friday. TransMedics Group, Inc. has a 52-week low of $20.36 and a 52-week high of $83.48. The company’s 50 day simple moving average is $68.92 and its 200-day simple moving average is $58.07. The company has a debt-to-equity ratio of 0.31, a quick ratio of 9.79 and a current ratio of 10.66.

TransMedics Group (NASDAQ:TMDX – Get Rating) last released its quarterly earnings results on Wednesday, February 22nd. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.07. TransMedics Group had a negative net margin of 38.77% and a negative return on equity of 29.82%. The business had revenue of $31.38 million for the quarter, compared to analyst estimates of $23.60 million. During the same quarter in the previous year, the business earned ($0.46) earnings per share. The firm’s revenue was up 224.5% compared to the same quarter last year. On average, equities research analysts anticipate that TransMedics Group, Inc. will post -0.89 EPS for the current fiscal year.

About TransMedics Group

(Get Rating)

TransMedics Group, Inc operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.